Abstract:OBJECTIVE Glucocorticoid (GC) has occupied a central role in the treatment of acute lymphoblastic leukemia due to its ability to induce apoptosis in neoplastic lymphoid cells. Glucocorticoid resistance is present among 20% initial acute lymphoblastic leukemia, even 80% refractory acute lymphoblastic leukemia. Glucocorticoid resistance has been an important determinant of clinical outcome. Glucocorticoid depends on glucocorticoid receptor (GR) to induce apoptosis. Glucocorticoid receptor, a number of nuclear hormone receptor superfamily, is mediated by many signal transduction systems. The mitogen-activated protein kinases (MAPK) superfamily of serine/threonine kinases has emerged as an important component of cellular signal transduction. Four MAP kinase families, ERK, p38 MAP kinase, JNK, and ERK5, have been well characterized. p38 MAPK usually plays a role in regulating apoptosis, cell cycle arrest and cytokines production, et al. In steroid resistance patients, IL-2 combined with IL-4 can decrease glucocorticoid receptor ligand-binding affinity via p38MAPK. In human alveolar epithelial A549 cells, dexamethasone could inhibit the activation of p38MAPK. It is unclear that the effect of p38MAPK on glucocorticoid receptor function induced by dexamethasone in CEM cells. This study aimed to investigate effect of p38 mitogen-activated protein kinase on glucocorticoid receptor function induced by dexamethasone in CEM cells. METHODS Cell viability was determined by trypan blue dye exclusion. Apoptosis was evaluated by morphology and flow cytometry. Glucocorticoid receptor protein and p-p38MAPK protein were analyzed by Western Blot. RESULTS When treatment with SB203580 and dexamethasone for 24 h to 72 h, the survival percentage was increased from 62.3%, 35.5% and 11.6% to 82.8%, 54.7% and 48.1%, respectively (P < 0.01). Co-treatment with SB203580 and dexamethasone resulted in the decrease of apoptotic percentage from 26.2% to 7.1% for 36 h (P < 0.01). p38 MAPK activation was apparent at 15 min, peaked at 1 h after dexamethasone treatment, and was sustained for 6 h. The phosphorylation was still observed at 48 h. Treatment with dexamethasone at 5 micromol/L for 12, 24, 36 and 48 h resulted in increase of GR(alpha) protein to 117%, 121%, 122% and 125% respectively. Unbinding to dexamethasone, GR(alpha) is in the cytoplasm. Nuclear-to-cytoplasmic ratio of GR(alpha) is 0.27. Treatment with dexamethasone at the same concentration and time resulted in the nuclear-to-cytoplasmic ratio increase to 0.48, 0.59, 0.95, 2.16 and 4.08 respectively. Combined treatment with SB203580 and dexamethasone resulted in the nuclear-to-cytoplasmic ratio decrease from 4.08 to 0.43 for 48 h (P < 0.05). The total GR(alpha) protein was unaffected. CONCLUSIONS Expression of GR(alpha) protein is upregulated and translocated into nucleus. p38MAPK enhances GR(alpha) protein translocation into nucleus.

Rapamycin Sensitizes Glucocorticoid Resistant Acute Lymphoblastic Leukemia Cem-C1 Cells to Dexamethasone Induced Apoptosis Through Both Mtor Suppression and Up-Regulation and Activation of Glucocorticoid Receptor

Rapamycin Sensitizes T-ALL Cells to Dexamethasone-Induced Apoptosis

Rapamycin Reverses Glucocorticoid Resistance in Human T-cell Acute Lymphoblastic Leukemia CEM-C1 Cells

Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma

Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G 1 cell cycle arrest and apoptosis

Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis

Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK.

Pro-apoptotic Protein BIM in Apoptosis of Glucocorticoid-Sensitive and -Resistant Acute Lymphoblastic Leukemia CEM Cells

Endoplasmic reticulum stress, unfolded protein response and autophagy contribute to resistance to glucocorticoid treatment in human acute lymphoblastic leukaemia cells

Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity

Abstract LB-75: Glucocorticoid Receptor Activation Inhibits P53-Induced Apoptosis of MCF10A Myc Cells Via Induction of Protein Kinase C Epsilon

[P38 Mitogen-Activated Protein Kinase Mediates Glucocorticoid Receptor Function Induced by Dexamethasone in Acute Lymphoblastic Leukemia Cells].

Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells

Glucocorticoid Resistance in Acute Lymphoblastic Leukemia:Molecular Mechanisms and Related Issues

Glucocorticoid Receptor Activation Inhibits P53-Induced Apoptosis of MCF10Amyc Cells Via Induction of Protein Kinase Cϵ

mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells

Rapamycin Enhances Apoptosis and Increases Sensitivity to Cisplatin In-Vitro

Rapamycin Interacts Synergistically with Idarubicin to Induce T-Leukemia Cell Apoptosis in Vitro and in A Mesenchymal Stem Cell Simulated Drug-Resistant Microenvironment Via Akt/Mammalian Target of Rapamycin and Extracellular Signal-Related Kinase Signaling Pathways

Anti-Leukemia Effect Of Rapamycin Alone Or Plus Daunorubicin On Acute Lymphoblastic Leukemia Cell Lines

Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy

Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia